Conclusion of a Basic Agreement for Cooperation and Collaboration on Development of Next-Generation Medical Technologies and Healthcare Services in the Kashiwa-no-ha Area
- Forming a Life Science Center Aimed at Curing and Conquering Cancer –

June 24, 2019
National Cancer Center Japan
Mitsui Fudosan Co., Ltd.
Miraca Holdings Inc..

Tokyo, Japan, July 24, 2019 – Mitsui Fudosan Co., Ltd., a leading global real estate company headquartered in Tokyo, National Cancer Center Japan (Headquarters: Chuo-ku, Tokyo; President: Hitoshi Nakagama; hereinafter “NCC”), and Miraca Holdings Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO Shigekazu Takeuchi; hereinafter “MiracaHD”) announced today that they have concluded a basic agreement on coordination and collaboration on development of next-generation medical technologies and healthcare services in the Kashiwa-no-ha area (Kashiwa City, Chiba Prefecture). With their tripartite collaboration to Cure and Conquer Cancer (“3C”), the three companies will now begin detailed discussions on specific initiatives.

The center for this initiative will be the Kashiwa-no-ha area in Kashiwa City, Chiba Prefecture, which has been built with the aim of realizing a smart city*1 through three urban development concepts: “A City of Health and Longevity,” “an Environmental Symbiotic City,” and “a City of New Industry Creation.”

The Kashiwa-no-ha area has a concentration of academic and research institutions, such as the National Cancer Center Hospital East and the Exploratory Oncology Research & Clinical Trial Center. An environment that produces new medical technologies and services is needed to serve as a testing ground for application of innovative seeds that lead to next-generation medical technologies. Creation of an environment where innovation can be supported through quality assurance and standardization of appropriate data and specimens based on a wealth of expertise is vital for the application of academic scholarship. Thus, to conquer and cure cancer, it is important to promote open innovation in the form of collaboration between industry, academia, and healthcare, and to advance research that adds “towns” to “industry, academia, and healthcare” through links with the local community and urban development. Conquering cancer requires coordinated efforts from the perspectives of medicine and the local community and urban development.

NCC, Mitsui Fudosan, and Miraca HD will each play an appropriate role aiming to achieve 3C. Mitsui Fudosan will coordinate and collaborate closely with its partners through the private-sector laboratory “Mitsui Link Lab Kashiwa-no-ha” (tentative name), which it is planning to set up in the area.

The three companies will use their respective strengths in close coordination and collaboration, carrying out the following roles. Their aim is to form a life science center in the Kashiwa-no-ha area, create next generation medical technologies and healthcare services in the area, and communicate and spread the results throughout not only Japan but also the world.

*1 The area around Kashiwa-no-ha Campus Station in Kashiwa City, Chiba Prefecture was chosen as a Smart City Model Project by the Ministry of Land, Infrastructure, Transport and Tourism on May 31, 2019.

Details of Coordination and Collaboration

• Preparation of incubation functions and infrastructure for research and technology development targeting “3C”
• Provision of a one-stop consultation service for academia and private companies
• Build partnerships with various academic institutions and private-sector companies

Roles of NCC, Mitsui Fudosan, and MIRACA HD

ＮＣＣ

At its Hospital East and the Exploratory Oncology Research & Clinical Trial Center on Kashiwa-no-ha Campus, NCC will provide consultation as needed to academic institutions and companies at Mitsui Link Lab Kashiwa-no-ha (tentative name) regarding communication of front-line medical needs and evaluation of new technologies, and so forth. Also, it will fulfill the role of an administrator to support research.

Mitsui Fudosan

Mitsui Fudosan will “Location Establishment” for creating new industries, such as a wet lab capable of advanced research and creative offices. It will also promote innovation using community networks such as LINK-J*2 and 31Ventures*3 to provide support for ventures.

Miraca HD

Miraca HD will undertake development provision and standardization of medical services including various kinds of testing, and provide seeds matching opportunities to help commercialize seeds.

*2 LINK-J is short for Life Science Innovation Network Japan, which supports exchanges between industry, academia, and government with a view to creating innovation in the life science field.
*3 31Ventures is a platform provided by Mitsui Fudosan for comprehensively supporting the growth of ventures based on “community,” “support” and “funding.”

Basic Information about Each Company

• About National Cancer Center Japan
  The National Cancer Center Hospital East was established in 1992 with the objective of creating new cancer therapies. It is a leading cancer specialized hospital in Japan, treating over 9,000 new patients each year. The Exploratory Oncology Research & Clinical Trial Center (NCC-EPOC), established in 2015, operates as a TR research and development center based on cross-organizational networks. It promotes the development of advanced cancer treatments and medical equipment through first-in-human trials of new medicines and physician-led therapeutic trials. On the Kashiwa Campus, both organizations work closely on international research and development, and have amassed a strong track record both in and outside Japan.
• About Mitsui Fudosan
  Mitsui Fudosan is a comprehensive developer that creates new value by striving to resolve social issues through urban development. At Kashiwa-no-ha Smart City, Mitsui Fudosan aims to create a smart, compact city driven by data through the introduction of new technologies such as AI and IoT. It has been selected by the Ministry of Land, Infrastructure, Transport and Tourism as an advanced model project for a smart city towards realizing “Society 5.0.” Going forward, Mitsui Fudosan will work on developing smart medical institution services for health and medicine.
• About Miraca Holdings
  Miraca HD provides high quality services related to clinical testing, primarily through SRL, Inc. and Fujirebio Inc. It is also a leading company in the manufacture, development, and sale of in vitro diagnostics reagents and　testing instruments, serving mainly medical institutions and contributing to the advance of medicine. Amid a changing oncology landscape, Miraca HD is developing tumor markers, setting up a specialized department in the cancer genome field, and supporting clinical research.

About Mitsui Link Lab Kashiwa-no-ha (Tentative Name)

Planned construction site

Perspective image